Methods and systems for business development and licensing and competitive intelligence

• US 9,721,217 B2
• Filed: 06/10/2013
• Issued: 08/01/2017
• Est. Priority Date: 12/09/2012
• Status: Active Grant

• Current Assignee: Camelot UK Bidco Limited (Clarivate Plc)
• Original Assignee: Camelot UK Bidco Limited (Clarivate Plc)
• Inventors: Gordon, Mark, Miller, Tim, Olof-Ors, Mans A, Bugrim, Andrej, Williams, Colin, Malik, Hassan
• Primary Examiner(s): KANAAN, MAROUN P
• Application Number:
  US13/914,393
• Publication Number:
  US 20140164008A1
• Time in Patent Office: 1,513 Days
• CPC Class Codes: G06Q 10/06 Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
• CPC Class Codes: G06Q 30/018 Certifying business or products
• CPC Class Codes: G06Q 50/184 Intellectual property management
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

Systems and method for making intelligent business development and licensing decisions are disclosed. The present invention generally relates to an analytical tool that combines multiple data and content sets based on user selected factors and presents the data in the form of manipulatable visualizations to facilitate decision making to address a specific business problem. More specifically, this invention relates to providing a single portal for access to a decision support system that enables the visualization of data from multiple content and data sets to facilitate decision making related to opportunities analysis, asset acquisition, and intellectual property licensing.

Claims

1. A computer-implemented method comprising:

a. receiving by a graphical user interface (“

GUI”

) element an input representing a user selected medical issue;

b. indexing and linking, by an indexing ontologies engine, documents and information in a plurality of databases to generate a set of enriched information to facilitate searching for data relevant to the medical issue;

c. identifying by use of a processor executing a first identification module comprising a set of code a factor associated with a medical issue;

d. controlling, by an enterprise server bus, access to a set of assets associated with the medical issue;

e. identifying by the processor executing a second identification module the set of assets associated with the medical issue based upon the set of enriched information and a set of customizable factors, the set of customizable factors being associated with a user-selected set of weighting factors and comprising a set of scientific factors and a set of business factors, the set of customizable factors including one or more from the group consisting of;

drug pipeline data;

data on drugs in development;

a set of financial metrics associated with a set of companies associated with the medical issue;

a set of investment data related to the set of companies; and

the relevance of various biological targets and the drugs in development against them to the area of focus;

f. determining for presentation via the GUI a first graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue;

g. receiving a further input representing a user modification of at least one of the set of customizable factors;

h. transforming the first graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue into a second graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue based on the user modification; and

i. generating by a representation module for presentation via a display a manipulatable representation of the set of assets.

2. The method of claim 1 wherein the set of assets is further used to identify a second set of assets.

3. The method of claim 2 wherein the set of assets and the second set of assets each is comprised of at least one from the group consisting of:

existing drug pipeline data, drug data identified as similar or related to the medical issue, existing financial information, existing disease and disease target research, news, company websites, blogs, conferencing databases, papers, patents, institutions conducting research on the assets or areas of specialization surrounding them, people identified as experts concerning an asset, results and presentations from scientific conferences, registration documents filed with the FDA, papers in peer reviewed journals, and clinical trials registries.

4. The method of claim 3 wherein the manipulatable representation comprises a comparison of an asset from the set of assets with another asset from the second set of assets.

5. The method of claim 1 wherein the factor comprises at least one of a disease, a condition, a gene, and a protein.

6. The method of claim 1 wherein the manipulatable representation is a visual representation.

7. The method of claim 6 wherein the visual representation is selected from among a target grid population, a target graph, a target map, and a target list.

8. The method of claim 6 wherein the visual representation is manipulatable by at least one of a company attribute and a drug attribute.

9. The method of claim 8 wherein the company attribute is at least one of a company type, a funding type, a deal type, and a company history, and wherein the drug attribute is at least one of an indication, an action, a development status, a technology, an indication of whether the user'"'"'s company has previously assessed the drug, and an existing partnership.

10. The method of claim 1 wherein the set of multiple business factors comprises at least one of partnership status, organization type, publication maturity, target similarity, licensing activity, mergers and acquisitions activity, financial metrics, sales forecasts, private equity funding, existing contracts, types of funding, and prior or current assessment by the user'"'"'s company.

11. The method of claim 1 wherein the set of multiple scientific factors comprises at least one of drug, drug molecule type, drug development status, related patents, drug licensing deals, drug licensing partnerships, clinical trials, FDA decisions, other regulatory body decisions, disease targets, and drug pathways.

12. The method of claim 1 wherein the set of assets comprises at least one of a company, a partnership, and a set of rights.

13. The method of claim 10 wherein the set of rights comprises at least one of a license, assignment, contract, and sale.

14. The method of claim 1 wherein the medical issue is from the group consisting of drug, disease, therapy, treatment, medical device, biological target and area of focus in biopharmaceutical research and development.

15. A computer-based system comprising:

a. a server comprising a processor adapted to execute code and a memory for storing executable code;

b. a graphical user interface (“

GUI”

) module comprising a GUI element configured to receive an input representing a user selected medical issue;

c. an indexing ontologies engine configured to index and link documents and information in a plurality of databases to generate a set of enriched information to facilitate searching for data relevant to the medical issue;

d. an enterprise server bus adapted to control access to a set of assets associated with the selected medical issue;

e. a first identification module configured to identify a factor associated with the medical issue;

f. a second identification module configured to identify the set of assets associated with the medical issue based upon the set of enriched information and a set of customizable factors, the set of customizable factors being associated with a user selected set of weighting factors and comprising a set of multiple scientific factors and a set of multiple business factors, the set of customizable factors including one or more from the group consisting of;

drug pipeline data;

data on drugs in development;

a set of financial metrics associated with a set of companies associated with the medical issue;

a set of investment data related to the set of companies; and

the relevance of various biological targets and the drugs in development against them to the area of focus;

g. a representation module configured to determine for presentation via the GUI module a first graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue;

h. the GUI module further configured to receive a further input representing a user modification of at least one of the set of customizable factors; and

i. the representation module further configured to transform the first graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue into a second graphical expression of the relative degree of relatedness of the set of assets associated with the medical issue based on the user modification, and to generate for presentation by a display associated with a user access device a manipulatable representation of the set of assets.

16. The system of claim 15 wherein the set of assets is further used to identify a second set of assets.

17. The system of claim 16 wherein the set of assets and the second set of assets each is comprised of at least one from the group consisting of:

existing drug pipeline data, drug data identified as similar or related to the medical issue, existing financial information, existing disease and disease target research, news, company websites, blogs, conferencing databases, papers, patents, institutions conducting research on the assets or areas of specialization surrounding them, people identified as experts concerning an asset, results and presentations from scientific conferences, registration documents filed with the FDA, papers in peer reviewed journals, and clinical trials registries.

18. The system of claim 17 wherein the manipulatable representation comprises a comparison of an asset from the set of assets with another asset from the second set of assets.

19. The system of claim 15 wherein the factor comprises at least one of a disease, a condition, a gene, and a protein.

20. The system of claim 15 wherein the manipulatable representation is a visual representation.

21. The system of claim 20 wherein the visual representation is selected from among a target grid population, a target graph, a target map, and a target list.

22. The system of claim 20 wherein the visual representation is manipulatable by at least one of a company attribute and a drug attribute.

23. The system of claim 22 wherein the company attribute is at least one of a company type, a funding type, a deal type, and a company history, and wherein the drug attribute is at least one of an indication, an action, a development status, a technology, an indication of whether the user'"'"'s company has previously assessed the drug, and an existing partnership.

24. The system of claim 15 wherein the set of multiple business factors comprises at least one of partnership status, organization type, publication maturity, target similarity, licensing activity, mergers and acquisitions activity, financial metrics, sales forecasts, private equity funding, existing contracts, types of funding, and prior or current assessment by the user'"'"'s company.

25. The system of claim 15 wherein the set of multiple scientific factors comprises at least one of drug, drug molecule type, drug development status, related patents, drug licensing deals, drug licensing partnerships, clinical trials, FDA decisions, other regulatory body decisions, disease targets, and drug pathways.

26. The system of claim 15 wherein the set of assets comprises at least one of a company, a partnership, and a set of rights.

27. The system of claim 26 wherein the set of rights comprises at least one of a license, assignment, contract, and sale.

28. The system of claim 15 wherein the medical issue is from the group consisting of drug, disease, therapy, treatment, medical device, biological target and area of focus in biopharmaceutical research and development.